IL136314A0 - Integrin receptor antagonists - Google Patents

Integrin receptor antagonists

Info

Publication number
IL136314A0
IL136314A0 IL13631498A IL13631498A IL136314A0 IL 136314 A0 IL136314 A0 IL 136314A0 IL 13631498 A IL13631498 A IL 13631498A IL 13631498 A IL13631498 A IL 13631498A IL 136314 A0 IL136314 A0 IL 136314A0
Authority
IL
Israel
Prior art keywords
beta
alpha
receptor antagonists
integrin receptor
compounds
Prior art date
Application number
IL13631498A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9810182.7A external-priority patent/GB9810182D0/en
Priority claimed from GBGB9810882.2A external-priority patent/GB9810882D0/en
Priority claimed from GBGB9810892.1A external-priority patent/GB9810892D0/en
Priority claimed from GBGB9811283.2A external-priority patent/GB9811283D0/en
Priority claimed from GBGB9812686.5A external-priority patent/GB9812686D0/en
Priority claimed from GBGB9822331.6A external-priority patent/GB9822331D0/en
Priority claimed from GBGB9822701.0A external-priority patent/GB9822701D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of IL136314A0 publication Critical patent/IL136314A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Vending Machines For Individual Products (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
IL13631498A 1997-12-17 1998-12-14 Integrin receptor antagonists IL136314A0 (en)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US6991097P 1997-12-17 1997-12-17
US7919798P 1998-03-24 1998-03-24
US7994498P 1998-03-30 1998-03-30
US8039798P 1998-04-02 1998-04-02
US8325198P 1998-04-27 1998-04-27
GBGB9810182.7A GB9810182D0 (en) 1998-05-13 1998-05-13 Vitronectin receptor antagonists
GBGB9810882.2A GB9810882D0 (en) 1998-05-20 1998-05-20 Vitronectin receptor antagonists
GBGB9810892.1A GB9810892D0 (en) 1998-05-20 1998-05-20 Vitronectin receptor antagonists
GBGB9811283.2A GB9811283D0 (en) 1998-05-26 1998-05-26 Vironectin receptor antagonists
GBGB9812686.5A GB9812686D0 (en) 1998-06-12 1998-06-12 Vitronectin receptor antagonists
US9262498P 1998-07-13 1998-07-13
US9258898P 1998-07-13 1998-07-13
US9994898P 1998-09-11 1998-09-11
GBGB9822331.6A GB9822331D0 (en) 1998-10-13 1998-10-13 Vitronectin receptor antagonists
GBGB9822701.0A GB9822701D0 (en) 1998-10-16 1998-10-16 Intergrin receptor antagonists
PCT/US1998/026568 WO1999031099A1 (en) 1997-12-17 1998-12-14 Integrin receptor antagonists

Publications (1)

Publication Number Publication Date
IL136314A0 true IL136314A0 (en) 2001-05-20

Family

ID=27585232

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13631498A IL136314A0 (en) 1997-12-17 1998-12-14 Integrin receptor antagonists

Country Status (23)

Country Link
EP (1) EP1040111B1 (ru)
JP (2) JP3589633B2 (ru)
KR (2) KR20030048081A (ru)
AT (1) ATE298338T1 (ru)
AU (1) AU741769B2 (ru)
BG (1) BG104601A (ru)
CA (1) CA2315189C (ru)
DK (1) DK1040111T3 (ru)
EA (1) EA003095B1 (ru)
EE (1) EE200000360A (ru)
ES (1) ES2243016T3 (ru)
HU (1) HUP0100178A3 (ru)
IL (1) IL136314A0 (ru)
IS (1) IS5513A (ru)
NO (1) NO317975B1 (ru)
NZ (1) NZ504896A (ru)
PE (1) PE20000010A1 (ru)
PL (1) PL341095A1 (ru)
PT (1) PT1040111E (ru)
SI (1) SI1040111T1 (ru)
SK (1) SK9162000A3 (ru)
TR (1) TR200001752T2 (ru)
WO (1) WO1999031099A1 (ru)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1047425A4 (en) * 1997-12-17 2009-04-22 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
WO2000009503A1 (en) * 1998-08-13 2000-02-24 Merck & Co., Inc. Integrin receptor antagonists
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
EP1140183A1 (en) * 1998-12-23 2001-10-10 G.D. Searle & Co. Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
CN1353706A (zh) 1999-04-13 2002-06-12 巴斯福股份公司 整合素受体配体
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
IL146378A0 (en) 1999-06-02 2002-07-25 Merck & Co Inc Alpha v integrin receptor antagonists
DE19936780A1 (de) * 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
JP2003510360A (ja) * 1999-10-04 2003-03-18 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
ES2202191T3 (es) * 1999-11-08 2004-04-01 MERCK & CO., INC. Procedimiento y productos intermedios para la preparacion de antagonistas de la imidazolidinona-alfa v-integrina.
US6407241B1 (en) 1999-11-08 2002-06-18 Merck & Co., Inc. Process and intermediates for the preparation of imidazolidinone αv integrin antagonists
GB2356630A (en) 1999-11-10 2001-05-30 Merck & Co Inc Intermediates used in the preparation of tetrahydronaphthyridine
ATE258177T1 (de) 1999-11-23 2004-02-15 Merck & Co Inc Verfahren für die herstellung und zwischenprodukte von tetrahydro-(1,8)- naphthyridin
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
JP4787447B2 (ja) * 2000-01-20 2011-10-05 メルク・シャープ・エンド・ドーム・コーポレイション αｖインテグリン受容体拮抗薬
WO2001079173A2 (en) 2000-04-17 2001-10-25 Celltech R & D Limited Enamine derivatives as cell adhesion molecules
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
EP1301488A1 (en) 2000-07-07 2003-04-16 Celltech R&D Limited Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
AU2001275724A1 (en) 2000-08-02 2002-02-13 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
AU9088401A (en) * 2000-09-13 2002-03-26 Merck & Co Inc Alpha v integrin receptor antagonists
AU2001292598B2 (en) 2000-09-14 2006-06-29 Merck & Co., Inc. Alpha V integrin receptor antagonists
WO2002053099A2 (en) * 2001-01-03 2002-07-11 Merck & Co., Inc. Methods and compositions for treating periodontal disease
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
RU2316337C2 (ru) 2001-04-24 2008-02-10 Мерк Патент Гмбх КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US20070299114A1 (en) * 2004-10-05 2007-12-27 Shionogi & Co., Ltd. Biaryl Derivatives
EP2338518A1 (en) 2006-01-18 2011-06-29 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
DE102006024024A1 (de) 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
BRPI0806596A2 (pt) 2007-01-18 2013-07-23 Merck Patent Ges Mit Berchraenkter Haftung medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer
AU2009223235B2 (en) * 2008-03-14 2014-09-11 Merck Sharp & Dohme Corp. Integrin targeting agents and in-vivo and in-vitro imaging methods using the same
DE102008060967A1 (de) 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
MX2011012491A (es) 2009-05-25 2011-12-14 Merck Patent Gmbh Administracion continua de cilengitida en tratamientos contra el cancer.
UA109650C2 (xx) 2010-02-27 2015-09-25 Біс-арилзв'язані арилтриазолони та їх застосування
DE102010040187A1 (de) 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
DE102010040924A1 (de) 2010-09-16 2012-03-22 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung
US8901144B2 (en) * 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
RU2698195C2 (ru) * 2013-02-07 2019-08-23 Сайфлуор Лайф Сайенсиз, Инк Фторсодержащие антагонисты интегрина
RS62591B1 (sr) 2013-09-24 2021-12-31 Fujifilm Corp Novo jedinjenje koje sadrži azot ili njegova so ili njihov kompleks sa metalom
BR112016027778A2 (pt) 2014-05-30 2017-08-15 Pfizer Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica
PL3215498T3 (pl) 2014-11-03 2019-02-28 Bayer Pharma Aktiengesellschaft Pochodne fenylotriazolu podstawione hydroksyalkilem i ich zastosowania
EP3259271B1 (en) * 2015-02-19 2021-05-05 SciFluor Life Sciences, Inc. Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
WO2017189828A1 (en) * 2016-04-27 2017-11-02 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
EP4147698A1 (en) 2017-02-28 2023-03-15 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
MX2019010267A (es) 2017-02-28 2020-02-05 Morphic Therapeutic Inc INHIBIDORES DE INTEGRINA AVß6.
BR112021003859A2 (pt) 2018-08-29 2021-05-18 Morphic Therapeutic, Inc. inibindo integrina avss6
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1598073A (en) * 1976-12-18 1981-09-16 Beecham Group Ltd 8,10,12-triazaprostaglandins
AU4806879A (en) * 1978-06-15 1979-12-20 Beecham Group Limited 1,2,4 triazole derivatives
DE3042466A1 (de) * 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
EP0531382A1 (en) * 1990-05-25 1993-03-17 G.D. Searle & Co. N-substituted-1,2,4-triazolone compounds for treatment of cardiovascular disorders
US5416099A (en) * 1991-10-29 1995-05-16 Merck & Co., Inc. Fibrinogen receptor antagonists
JP2001527506A (ja) * 1992-02-11 2001-12-25 スミスクライン・ビーチャム・コーポレイション ＣｏＡ−ＩＴおよびＰＡＦ阻害剤
JPH10501222A (ja) * 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物

Also Published As

Publication number Publication date
NZ504896A (en) 2002-10-25
PE20000010A1 (es) 2000-01-29
ES2243016T3 (es) 2005-11-16
CA2315189C (en) 2005-04-19
SI1040111T1 (en) 2005-10-31
AU1914499A (en) 1999-07-05
HUP0100178A3 (en) 2002-12-28
KR20030048081A (ko) 2003-06-18
AU741769B2 (en) 2001-12-06
DK1040111T3 (da) 2005-10-10
JP2004300158A (ja) 2004-10-28
EP1040111A1 (en) 2000-10-04
PL341095A1 (en) 2001-03-26
PT1040111E (pt) 2005-10-31
ATE298338T1 (de) 2005-07-15
JP3589633B2 (ja) 2004-11-17
KR20010024748A (ko) 2001-03-26
EA200000653A1 (ru) 2000-12-25
CA2315189A1 (en) 1999-06-24
JP2002508374A (ja) 2002-03-19
HUP0100178A2 (hu) 2001-11-28
EA003095B1 (ru) 2002-12-26
BG104601A (bg) 2001-01-31
EP1040111B1 (en) 2005-06-22
WO1999031099A1 (en) 1999-06-24
SK9162000A3 (en) 2001-03-12
EE200000360A (et) 2001-12-17
NO20003113D0 (no) 2000-06-16
NO20003113L (no) 2000-08-16
IS5513A (is) 2000-05-26
TR200001752T2 (tr) 2000-12-21
NO317975B1 (no) 2005-01-17

Similar Documents

Publication Publication Date Title
IL136314A0 (en) Integrin receptor antagonists
PL341215A1 (en) Antagonists of integrin receptors
EP1044001A4 (en) INTEGRINE RECEPTOR ANTAGONISTS
DE69720771D1 (en) Integrin antagonist
CA2277273A1 (en) Integrin antagonists
ES2185009T3 (es) Antagonistas de alfa y beta 3'.
IL146378A0 (en) Alpha v integrin receptor antagonists
AU7793501A (en) Alpha v integrin receptor antagonists
YU38300A (sh) Antagonisti integrinskog receptora
YU38200A (sh) Antagonisti integrinskog receptora
ECSP992897A (es) Antagonistas del receptor de integrina